期刊文献+

原代培养的人成骨肉瘤细胞SOSP-9607体外药敏实验研究 被引量:1

A study on the drug sensitive test of primary osteosarcoma cell SOSP-9607
下载PDF
导出
摘要 目的通过原代培养的人成骨肉瘤细胞SOSP-9607的药敏感实验,研究骨肉瘤药物敏感性以及个体化治疗的可行性,从而提高骨肉瘤的治愈率。方法收集新鲜骨肉瘤组织建立SOSP-9607细胞系,以MTT比色法和流式细胞术观察5种常用化疗药对骨肉瘤细胞增殖和细胞周期时相的影响。结果骨肉瘤细胞对MTX,紫杉醇和5-FU敏感性强,生长抑制率达到51.16,49.24和42.63;流式细胞术结果显示G0/G1期细胞增多,S期细胞减少。结论骨肉瘤细胞的化疗药物敏感试验对选择敏感化疗药物开展个体化化疗,提高骨肉瘤治愈率有重要的意义。 Objeelive According to primary culture osteosarcoma cell SOSP-9607 drug sensitiveness test to study osteosarcoma drug sensitivity and improve the rate of osteosarcoma treatment. Methods SOSP-9607 cells were prepared from fresh osteosarcoma tissue. Observing the influence of five kinds of chems-drug to the cell proliferation and cell cycle of esteosareoma cell by MTT eolorimetry and flow eytometry. Results Osteosarcoma cells were more sensitive to MTX, Paclitaxe and 15-FU. The result of MTT showed the inhibitory rate were 51.16,49.24 and 42.63 respectively.The result of flow cytometry showed that G0/G1 stage cells of osteosarcoma increased and S stage ceils deceased. Coudusion The chemothempeuties drug sensitivity test of osteosareoma cells plays an important rule to improve curative effect.
出处 《中国实验诊断学》 2008年第10期1217-1219,共3页 Chinese Journal of Laboratory Diagnosis
关键词 骨肉瘤 药敏实验 细胞周期 ostesaroma drug sensitive test cell cycle
  • 相关文献

参考文献8

二级参考文献52

  • 1辛颖,倪劲松,王心蕊,石博,王越晖,吴家祥.20(S)-人参皂苷Rg3抗B16黑色素瘤转移的作用[J].吉林大学学报(医学版),2004,30(4):540-542. 被引量:40
  • 2司徒镇强,吴军正,主编.细胞培养.第1版.西安:世界图书出版公司,1996,134-135.
  • 3David LS,Robert DC,Lealic AL,主编.细胞实验指南.黄培堂,主译.第1版.北京:科学出版社,2001.113-114
  • 4Reinecke P, Knopf C, Schmitz M, et al. Growth inhibitory effects of paclitaxel on human epithelioid sarcoma in vitro: heterogeneity of response and the multidrug resistance phenotype. Cancer, 2000, 88: 1614-1622.
  • 5Swanson PE, Carroll SB, Zhang XF, et al. Spontaneous prematurechromosome condensation, micronucleus formation, and non-apop-totic cell death in heated HeLa S3 cells: ultrastructural observations. Am J Pathol, 1995, 146: 963-971.
  • 6Mross K, Hollander N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol, 2000, 45:463 -470.
  • 7Nannan Panday VR, de Wit R, Schornagel JH, et al. Pharmacoki netics of paclitaxel administered in combination with cisplatin etoposide and bleomycin in patients with advanced solid tumours.Cancer Chemother Pharmacol, 1999, 44: 349-353.
  • 8Bhalla KN, Kumar GN, Walle UK, et al. Phase Ⅰ and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplat inum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res, 1999, 5: 1723-1730.
  • 9Maier-Lenz H, Hauns B, Haering B, et al. Phase Ⅰ study of paclitaxel administered as a l-hour infusion: toxicity and pharmacoki netics. Semin Oncol, 1997, 24 (6 Suppl 19): 16-19.
  • 10Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc, 1994, 69: 341-345.

共引文献26

同被引文献16

  • 1黄伟,张瑶珍,周剑锋,刘文励.长春新碱对K562细胞plk1和γ-微管蛋白表达影响的研究[J].中国药理学通报,2005,21(3):295-298. 被引量:12
  • 2吴江,钱宝华,刘书逊,王卓,花美仙,郭峰.长春新碱载体红细胞的体外抗肿瘤作用[J].解放军医学杂志,2005,30(7):593-595. 被引量:11
  • 3张文韬,屠重棋,刘洋,李胜富.人成骨肉瘤顺铂耐药细胞系的建立[J].四川大学学报(医学版),2006,37(2):262-265. 被引量:4
  • 4Oda Y, Matsumoto Y, Harimaya K, et al. Establishment of new multidrug-resistant human osteosarcoma cell lines [J]. Oncol Rep, 2000, 7 (4); 859-866.
  • 5Susin SA, Zamzami N, Kroemer G. Mitochondria regulators of apoptosis: doubt no more [J]. Biochim Biophys Acta, 1998, 1366 (1/2): 151-165.
  • 6Heath-Engel HM, Shore GC. Mitochondrial membrane dynamics cristae remodeling and apoptosis [J]. Biochim Biophys Acta, 2006, (13): 570-576.
  • 7Scotlandi K, Picci P, Kovar H. Targeted therapies in bone sarcomas [J]. Curr Cancer Drug Targets, 2009, 9 (7): 843-853.
  • 8Bacci G, Lari S. Current treaunent of high grade osteosacoma of the extremity [J]. J Chemother, 2001, 13(3): 235-243.
  • 9Nie F, Zhang X, Qi Q, et al. Reactive oxygen species accumulation contributes to gambogic acid-induced apoptosis in human hepatoma SMMC-7721 cells [J]. Toxicology, 2009, 260 (1-3): 60-67.
  • 10Murayama, Kawasoe T, Yamashita Y, et al. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines [J]. Anticancer Res, 2008, 28 (4B): 2147-2154.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部